Critical appraisal:Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012 2

From Cancer Guidelines Wiki

Risk of bias assessment: randomised controlled trial

Was the trial double-blinded?
Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
No concealment or unclear (e.g. no approach described, open randomisation lists, person doing recruitment tossing a coin).
Were all randomised participants included in the analysis?
No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
How was the allocation schedule generated?
Inadequate or not reported
Overall risk of bias
High risk of bias Additional comments: trial was not blinded and did not describe treatment allocation, intention to treat population


Jutta's tick icon.png This appraisal has been completed.


Article
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 Jul 12;367(2):107-14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22663011.
Assigned to
User:Cecilia.taing
Topic area
Guidelines:Melanoma
Clinical question
Form
Form:Quality appraisal rct


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment